All AbMole products are for research use only, cannot be used for human consumption.
Onvansertib (PCM-075, NMS-1286937, NMS-P937) is a first-in-class, third-generation, oral, highly selective PLK1 inhibitor that induces tumor cell arrest in the G2/M phase and triggers apoptosis. It has a median IC50=136nM against a variety of CRC cell lines and inhibits xenograft models such as HT-29, HCT-116, and Colo-205 well.
| Molecular Weight | 532.52 |
| Formula | C24H27F3N8O3 |
| CAS Number | 1034616-18-6 |
| Solubility (25°C) | DMSO 21 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PLK Products |
|---|
| BI 2536
BI 2536 is a novel, highly selective, potent dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. |
| BI 6727
BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk1) with an IC50 of 0 .87 nM. |
| GSK461364
GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM. |
| Rigosertib sodium
Rigosertib sodium is a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K). |
| GW843682X
GW 843682X is a PLK inhibitor for PLK1 and PLK3 with IC50 of 2.2 nM and 9.1 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
